Atrial fibrillation: from ion channels to bedside treatment options

Journal of Electrocardiology

Volumn 42, Issue 6, 2009, Pages 660-670

  Singh, Bramah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiarrhythmic; Atrial fibrillation; Ion channels

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 5 [1 (ALPHA ETHYLIMINO 3,4 DIMETHOXYBENZYL) 1,2,3,4 TETRAHYDRO 6 QUINOLINYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; AAP 10; AMIODARONE; ANTIARRHYTHMIC AGENT; ATI 2042; AVE 1231; AZIMILIDE; BENZOFURAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CK 3579; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; ION CHANNEL; LIDOCAINE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RANOLAZINE; ROTIGAPTIDE; S 20951; S 9947; SOTALOL; SSR 149744C; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART REPOLARIZATION; ION TRANSPORT; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM;

ATRIAL FIBRILLATION; HEART CONDUCTION SYSTEM; HUMANS; ION CHANNEL GATING; ION CHANNELS; MODELS, CARDIOVASCULAR;

EID: 70350221689     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2009.04.002     Document Type: Review

References (102)

1. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27 (2006) 1979
2. Tsang T.S., Miyasaka Y., Barnes M.E., and Gersh B.J. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis 48 (2005) 1
3. Go A.S. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol 14 (2005) 56
4. Shiroshita-Takeshita A., Brundel B.J., and Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 13 (2005) 181
5. Nattel S., and Ehrlich J.R. Atrial fibrillation. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 512
6. Katz A.M. Cardiac ion channels. N Engl J Med 328 (1993) 1244
7. Whalley D.W., Wendt D.J., and Grant A.O. Basic concepts in cellular cardiac electrophysiology: Part I: ion channels, membrane currents, and the action potential. Pacing Clin Electrophysiol 18 (1995) 1556
8. Ackerman M.J., and Clapham D.E. Normal cardiac electrophysiology. Understanding the action potential in the human heart. In: Chien K.R. (Ed). Molecular basis of cardiovascular disease: a companion to Braunwald's heart disease (1998), W.B. Saunders, Philadelphia 281
9. Couette B., Marger L., Nargeot J., and Mangoni M.E. Physiological and pharmacological insights into the role of ionic channels in cardiac pacemaker activity. Cardiovasc Hematol Disord Drug Targets 6 (2006) 169
10. Li R.A., Tomaselli G.F., and Marbán E. Structural and molecular bases of ion channel function. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 1
11. Bers D.M. Cardiac calcium channels. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 10
12. Oudit G.Y., Ramirez R.F., and Backx H. Voltage-regulated potassium channels. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 19
13. Van Gelder I.C., and Hemels M.E. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 8 (2006) 943
14. Allessie M., Ausma J., and Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54 (2002) 230
15. Brundel B.J., Van Gelder I.C., Henning R.H., et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 103 (2001) 684
16. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219
17. Nattel S., Shiroshita-Takeshita A., Cardin S., and Pelletier P. Mechanisms of atrial remodeling and clinical relevance. Curr Opin Cardiol 20 (2005) 21
18. Brundel B.J., Henning R.H., Kampinga H.H., Van Gelder I.C., and Crijns H.J. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 54 (2002) 315
19. Brugada R. Molecular biology of atrial fibrillation. Minerva Cardioangiol 52 (2004) 65
20. Spach M.S., and Starmer C.F. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. Cardiovasc Res 30 (1995) 337
21. Rohr S. Role of gap junctions in the propagation of the cardiac action potential. Cardiovasc Res 62 (2004) 309
22. Wijffels M.C., Kirchhof C.J., Dorland R., and Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995) 1954
23. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180
24. Corradi D., Callegari S., Benussi S., et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch 445 (2004) 498
25. Xu J., Cui G., Esmailian F., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363
26. Cha Y.M., Redfield M.M., Shen W.K., and Gersh B.J. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109 (2004) 2839
27. Schoonderwoerd B.A., Van Gelder I.C., Van Veldhuisen D.J., Van den Berg M.P., and Crijns H.J. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 48 (2005) 153
28. Gillis A.M. Class I antiarrhythmic drugs: quinidine, procainamide, disopyramide, lidocaine, mexiletine, flecainide, and propafenone. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 911
29. Singh B.N. b-Blockers and calcium channel blockers as antiarrhythmic drugs. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 918
30. Singh B.N., and Sarma J.S. Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Ther 6 (2001) 69
31. Weirich J., and Antoni H. Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Res Cardiol 93 Suppl 1 (1998) 125
32. Anderson J.L., Platia E.V., Hallstrom A., et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 90 (1994) 2843
33. Roden D.M. Mechanisms and management of proarrhythmia. Am J Cardiol 82 (1998) 49I
34. Fetsch T., Bauer P., Engberding R., et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25 (2004) 1385
35. Bradley D., Creswell L.L., Hogue Jr. C.W., Epstein A.E., Prystowsky E.N., and Daoud E.G. Pharmacologic prophylaxis: American College of Chest Physicians Guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 128 (2005) 39S
36. Smith T.W., and Cain M.E. Class III antiarrhythmic drugs: amiodarone, ibutilide, and sotalol. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 932
37. Castro A., Bianconi L., and Santini M. New antiarrhythmic drugs for the treatment of atrial fibrillation. Pacing Clin Electrophysiol 25 (2002) 249
38. Khan I.A., Mehta N.J., and Gowda R.M. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 89 (2003) 239
39. Chevalier P., Durand-Dubief A., Burri H., Cucherat M., Kirkorian G., and Touboul P. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 41 (2003) 255
40. Letelier L.M., Udol K., Ena J., Weaver B., and Guyatt G.H. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 163 (2003) 777
41. Lafuente-Lafuente C., Mouly S., Longás-Tejero M.A., Mahe I., and Bergmann J.F. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166 (2006) 719
42. Vorperian V.R., Havighurst T.C., Miller S., and January C.T. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 30 (1997) 791
43. Riera A.R., Uchida A.H., Ferreira C., et al. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Cardiol J 15 (2008) 209
44. Singh B.N. b-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview. J Cardiovasc Pharmacol Ther 10 suppl 1 (2005) S3
45. Kathofer S., Thomas D., and Karle C.A. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 23 (2005) 217
46. Knobloch K., Brendel J., Rosenstein B., Bleich M., Busch A.E., and Wirth K.J. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. Med Sci Monit 10 (2004) BR221
47. 2+-exchange. Cardiovasc Res 73 (2007) 37
48. Löfberg L., Jacobson I., and Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace 8 (2006) 549
49. Kur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation 114 (2006) 1234
50. Oros A., Volders P.G., Beekman J.D., van der N.T., and Vos M.A. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block. Heart Rhythm 3 (2006) 1339
51. Wirth K.J., Brendel J., Steinmeyer K., Linz D.K., Rütten H., and Gögelein H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol 49 (2007) 197
52. Kur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 315 (2005) 1362
53. Lagrutta A., Wang J., Fermini B., and Salata J.J. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther 317 (2006) 1054
54. Persson F., Carlsson L., Duker G., and Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol 16 (2005) 329
55. Persson F., Carlsson L., Duker G., and Jacobson I. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol 46 (2005) 7
56. Fedida D., Orth P.M., Chen J.Y., et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 16 (2005) 1227
57. Bode F., Sachs F., and Franz M.R. Tarantula peptide inhibits atrial fibrillation. Nature 409 (2001) 35
58. KACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 54 (2006) 136
59. Hashimoto N., Yamashita T., Fujikura N., and Tsuruzoe N. NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs. Europace 9 (2007) 246
60. Nagasawa H., Fujiki A., Fujikura N., Matsuda T., Yamashita T., and Inoue H. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ J 66 (2002) 185
61. Sicouri S., Glass A., Belardinelli L., and Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 5 (2008) 1019
62. Burashnikov A., Di Diego J.M., Zygmunt A.C., Belardinelli L., and Antzelevitch C. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci 1123 (2008) 105
63. Singh S. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J Interv Card Electrophysiol 10 suppl 1 (2004) 71
64. Doggrell S.A. Tedisamil: master switch of nature?. Expert Opin Investig Drugs 10 (2001) 129
65. Hohnloser S.H., Dorian P., Straub M., Beckmann K., and Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 44 (2004) 99
66. Lee J.H., Rosenshtraukh L., Beloshapko G., and Rosen M.R. The electrophysiologic effects of ersentilide on canine hearts. Eur J Pharmacol 285 (1995) 25
67. Ravens U., Flüss O.M., Li Q., et al. Stereoselectivity of actions of the calcium sensitizer [+]-EMD 60263 and its enantiomer [-]-EMD 60264. Naunyn Schmiedebergs Arch Pharmacol 355 (1997) 733
68. Himmel H.M., Amos G.J., Wettwer E., and Ravens U. Effects of the calcium sensitizer [+]-EMD 60263 and its enantiomer [-]-EMD 60264 on cardiac ionic currents of guinea pig and rat ventricular myocytes. J Cardiovasc Pharmacol 33 (1999) 301
69. Kumagai K., Nakashima H., Gondo N., and Saku K. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol 14 (2003) 880
70. Clarke T.C., Thomas D., Petersen J.S., Evans W.H., and Martin P.E. The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol 147 (2006) 486
71. Stahlhut M., Petersen J.S., Hennan J.K., and Ramirez M.T. The antiarrhythmic peptide rotigaptide (ZP123) increases connexin43 protein expression in neonatal rat ventricular cardiomyocytes. Cell Commun Adhes 13 (2006) 21
72. Weng S., Lauven M., Schaefer T., Polontchouk L., Grover R., and Dhein S. Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. FASEB J 16 (2002) 1114
73. Dale K.M., and White C.M. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 41 (2007) 599
74. Touboul P., Brugada J., Capucci A., Crijns H.J., Edvardsson N., and Hohnloser S.H. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24 (2003) 1481
75. Singh B.N., Connolly S.J., Crijns H.J., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357 (2007) 987
76. Davy J.M. Dronedarone demonstrates additional rate control on top of standard pharmacotherapies in the treatment of atrial fibrillation. Circulation 112 Suppl 17 (2005) II577 [Abstract 2737]
77. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360 (2009) 668
78. Gautier P., Serre M., Cosnier-Pucheu S., et al. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol 45 (2005) 125
79. Kowey P.R., Aliot E.M., Capucci A., et al. Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter. Heart Rhythm 4 5 Suppl (2007) S72 [Abstract AB33-4]
80. Mátyus P., Varga I., Rettegi T., et al. Novel antiarrhythmic compounds with combined class IB and class III mode of action. Curr Med Chem 11 (2004) 61
81. Persson F., Andersson B., Duker G., Jacobson I., and Carlsson L. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur J Pharmacol 558 (2007) 133
82. Goldstein R.N., Khrestian C., Carlsson L., and Waldo A.L. AZD7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15 (2004) 1444
83. Crijns H.J., Van Gelder I.C., Walfridsson H., et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 3 (2006) 1321
84. Na and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 70 (2006) 486
85. Roy D., Rowe B.H., Stiell I.G., et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 44 (2004) 2355
86. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116 (2007) 1647
87. Murdock D.K., Overton N., Kersten M., Kaliebe J., and Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 8 (2008) 175
88. Burashnikov A., Di Diego J.M., Zygmunt A.C., Belardinelli L., and Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116 (2007) 1449
89. Pratt C.M., Singh S.N., Al-Khalidi H.R., et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 43 (2004) 1211
90. Kerr C.R., Connolly S.J., Kowey P., et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 98 (2006) 215
91. Morena A.P., Hayrapetyan V., Zhong G., Martinez A.D., and Beyer E.C. Homomeric and heteromeric gap junctions. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology from cell to bedside. 4th ed. (2004), W.B. Saunders, Philadelphia 120
92. Xing D., Kjølbye A.L., Nielsen M.S., et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 14 (2003) 510
93. Kjølbye A.L., Knudsen C.B., Jepsen T., Larsen B.D., and Petersen J.S. Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies. J Pharmacol Exp Ther 306 (2003) 1191
94. Eloff B.C., Gilat E., Wan X., and Rosenbaum D.S. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation 108 (2003) 3157
95. Haugan K., Olsen K.B., Hartvig L., et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol 16 (2005) 537
96. Hennan J.K., Swillo R.E., Morgan G.A., et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 317 (2006) 236
97. Haugan K., Marcussen N., Kjølbye A.L., Nielsen M.S., Hennan J.K., and Petersen J.S. Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 47 (2006) 236
98. Haugan K., Kjølbye A.L., Hennan J.K., and Petersen J.S. Rotigaptide (ZP123) reverts established atrial conduction velocity slowing. Cell Commun Adhes 12 (2005) 271
99. Guerra J.M., Everett T.H., Lee K.W., Wilson E., and Olgin J.E. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 114 (2006) 110
100. Haugan K., Miyamoto T., Takeishi Y., et al. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmacol Toxicol 99 (2006) 71
101. Shiroshita-Takeshita A., Sakabe M., Haugan K., Hennan J.K., and Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 115 (2007) 310
102. Zhong J.Q., Laurent G., So P.P., Hu X., Hennan J.K., and Dorian P. Effects of rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits. J Cardiovasc Pharmacol Ther 12 (2007) 69